|
|
Nombre comercial |
|
|
Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.
|
Idacrybin |
México |
Idamen |
Turquía |
Idamycin |
Canadá, Estados Unidos de América, México |
Idaralem |
Colombia, México |
Ondarubin |
México |
Rubix |
México |
Zavedos |
Alemania, Arabia Saudita, Argentina, Australia, Austria, Bélgica, Chile, Colombia, Croacia, Dinamarca, Ecuador, Eslovenia, España, Finlandia, Francia, Gran Bretaña, Grecia, Hungría, Irlanda, Islandia, Italia, Luxemburgo, Malasia, Marruecos, Noruega, Nueva Zelanda, Países Bajos, Polonia, Portugal, Rumania, ruso, Sudafrica, Suecia, Suiza, Tailandia, Venezuela |
|
|
|
|
Bibliografía : Idarubicin hydrochloride |
|
|
Tipo |
Publicación |
3 |
periódico |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
81 |
periódico |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
periódico |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
99 |
periódico |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
169 |
periódico |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
periódico |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
periódico |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
249 |
periódico |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
307 |
periódico |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
335 |
periódico |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
491 |
periódico |
Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184. |
632 |
periódico |
Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222. |
905 |
periódico |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
1410 |
periódico |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1423 |
periódico |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1496 |
periódico |
Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428. |
3474 |
Laboratorio |
Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
3526 |
Laboratorio |
Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010 |
3595 |
Laboratorio |
Aciclovir - Summary of Product Characteristics Hospira 2009 |
3637 |
Laboratorio |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014 |
4661 |
periódico |
Bourcier B, Lagarce R, Lebreton V. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization J Pharm Biomed Anal 2022 |
|
|